News

Article

Methylphenidate may impact corneal cells in children with ADHD

Author(s):

Key Takeaways

  • Methylphenidate-treated ADHD children had lower corneal endothelial cell counts than untreated and control groups, indicating potential ocular effects of the drug.
  • Untreated ADHD children showed lower ganglion cell layer measurements compared to those on methylphenidate and healthy controls, suggesting treatment impact on ocular health.
SHOW MORE

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

(Image Credit: AdobeStock/Bernard Chantal)

(Image Credit: AdobeStock/Bernard Chantal)

A study of the effects of methylphenidate in children with attention deficit hyperactivity disorder (ADHD) found lower corneal endothelial cell counts in those diagnosed with ADHD and undergoing treatment with methylphenidate compared with untreated children and a control group. The authors also reported that the ganglion cell layer (GCL) measurements were lower in the untreated children who were diagnosed with ADHD compared with those receiving methylphenidate and the control group.

First author Dilek Uzlu, MD, and colleagues from the Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey, reported their results in International Ophthalmology.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

This study focused on elucidating the ocular effects of methylphenidate on children diagnosed with ADHD and healthy controls. The participants were divided as follows: those diagnosed with ADHD and undergoing methylphenidate therapy (group 1), newly diagnosed untreated patients (group 2), and healthy, controls (group 3). The researchers evaluated the morphology and numbers of corneal endothelial cells, corneal thickness, choroidal thickness (CT), retinal thickness (RT), GCL, and retinal nerve fiber layer (RNFL) were evaluated.

Comparison of the 3 groups

Group 1 included 30 children (mean age, 10.53 ± 2.78 years) with ADHD treated with methylphenidate for a minimum of 1 year; group 2, 32 newly diagnosed untreated children (mean age, 9.21 ± 1.85 years); and group 3, 35 healthy children (mean age, 11.03 ± 3.01 years).

While the groups did not differ significantly (P > 0.05) in age, visual acuity level, or refractions, the researchers found that the endothelial cell counts and hexagonality values differed significantly between groups 1 and 2 (P = 0.041 and P = 0.031, respectively).

Other observations were that the GCL values differed between groups 1 and 2 and between groups 2 and 3 (P = 0.0001 and P = 0.02, respectively), but not between groups 1 and 3 (P = 0.551), the researchers reported.

The other parameters evaluated, ie, the central CT, central RT, and mean RNFL values did not differ significantly among the three groups (P > 0.05).

Uzlu and colleagues concluded, “Corneal endothelial counts were lower in the children diagnosed with ADHD and receiving methylphenidate therapy than in those not receiving treatment and the control group. In addition, GCL measurements were lower in the children diagnosed with ADHD and not using medication compared to those using methylphenidate and the control group.”

Reference
  1. Uzlu D, Bilginer SÇ, Yaşar Y, et al. An examination of the ocular effects of methylphenidate used in children and adolescents diagnosed with attention-deficit hyperactivity disorder. Int Ophthalmol. 2025;45. https://doi.org/10.1007/s10792-025-03471-z
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.